Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT03973112 | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 123 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04715321 | CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma | unknown | — | 120 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | unknown | Phase 2 | 35 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05166772 | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 22, 2021 | clinicaltrials |
| NCT03731910 | Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE | unknown | N/A | 35 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05161143 | Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05154812 | Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio | unknown | Early Phase 1 | 108 | Beijing Ditan HospitalOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05152498 | Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) | unknown | Early Phase 1 | 142 | Beijing Ditan HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05135364 | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | unknown | Phase 2 | 48 | Yue HanOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05088733 | Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA) | unknown | Early Phase 1 | 120 | Beijing Ditan HospitalOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05125094 | Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACE | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 18, 2021 | clinicaltrials |
| NCT04973098 | Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 | 13 | Peking UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05105815 | Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma | unknown | Early Phase 1 | 23 | Huashan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05088811 | The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma | unknown | — | 80 | Alexandria UniversityOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03042520 | Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment(LONGHEAD) | unknown | — | 200 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 2 | Oct 12, 2021 | clinicaltrials |
| NCT04443049 | To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. | unknown | N/A | 170 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04796025 | TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study(T-Double) | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04490694 | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03591705 | TACE-HAIC vs. HAIC for Potentially Resectable HCC | unknown | N/A | 240 | Sun Yat-sen UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04531228 | TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial(Thalen) | unknown | N/A | 60 | Yunfei YuanOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04814043 | PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial(PLATIC) | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05053386 | Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma | unknown | N/A | 186 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | unknown | Phase 1 / Phase 2 | 49 | Sichuan UniversityOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04724226 | Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma(C-couple) | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02921139 | Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)(TASABR) | unknown | N/A | 120 | Dalin Tzu Chi General HospitalOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05009550 | ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation | unknown | N/A | 30 | TC Erciyes UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT05007587 | Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | unknown | Early Phase 1 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04994236 | Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy | unknown | Phase 2 | 49 | Hui-Chuan SunOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04996446 | ALPPS Combined With Tislelizumab in Liver Malignancy | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04996459 | Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma | unknown | — | 40 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04639284 | Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC | unknown | — | 200 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04127396 | Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | unknown | Phase 4 | 72 | Beijing Ditan HospitalOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04920214 | Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC | unknown | — | 500 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 15, 2021 | clinicaltrials |
| NCT04961138 | Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma | unknown | N/A | 164 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jul 14, 2021 | clinicaltrials |
| NCT04961918 | The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04955119 | Fusion Imaging Contrast-enhanced Ultrasound LI-RADS | unknown | N/A | 132 | Tianjin Third Central HospitalOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04947956 | Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma | unknown | — | 1,000 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 1, 2021 | clinicaltrials |
| NCT04806243 | Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） | unknown | Phase 2 | 69 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04331743 | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04913480 | SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 37 | The University of Hong KongOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02964260 | RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma | unknown | N/A | 410 | Sun Yat-sen UniversityOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04517227 | The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | unknown | N/A | 30 | Fudan UniversityOTHER | 0 | May 3, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 18, 2022source: clinicaltrials